Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
Zacks Investment Research on MSN
NVO Stock Up as Amycretin Shows Strong Weight Loss in Type 2 Diabetes
Shares of Novo Nordisk NVO were up 4.7% yesterday, after the company announced positive data from a phase II study evaluating its investigational pipeline candidate, amycretin, in people with type 2 ...
Can Novo Nordisk get its comeback going in 2026? Let's discuss two things that could materialize for the company next year ...
Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it ...
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
An Indian court has allowed Dr. Reddy’s Laboratories Ltd. to manufacture and export generic versions of Novo Nordisk A/S’s ...
GLP-1 drugs, which include Ozempic and Wegovy, have become one of the most closely watched experimental approaches for ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
The price/sales TTM, EV/Sales TTM, and EV/EBITDA TTM of Novo, as compared to its peers, repeat substantially the same story ...
Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback